Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Misses Estimates By $0.05 EPS

Dianthus Therapeutics (NASDAQ:DNTH) issued its earnings results on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05), FiscalAI reports. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.

Dianthus Therapeutics Trading Up 4.6%

NASDAQ DNTH traded up $4.89 on Tuesday, hitting $110.92. 636,619 shares of the company were exchanged, compared to its average volume of 978,479. Dianthus Therapeutics has a 1-year low of $18.08 and a 1-year high of $114.55. The firm has a 50 day moving average of $93.02 and a two-hundred day moving average of $79.05. The company has a market cap of $6.06 billion, a P/E ratio of -26.86 and a beta of 1.22.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DNTH. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush raised their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Caitong International Asset Management Co. Ltd acquired a new position in Dianthus Therapeutics during the 4th quarter valued at about $40,000. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $64,000. Royal Bank of Canada raised its stake in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the last quarter. Finally, Quarry LP acquired a new position in Dianthus Therapeutics in the fourth quarter valued at approximately $99,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.